3 Results for "

hypercalcemia associated with malignancy

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "hypercalcemia associated with malignancy" in MCE Product Catalog:

Cat. No.: HY-16498
CAS No.: 848084-83-3
Synonyms: PCK-3145
Target:  

Apoptosis PTHR

Research Areas:  

Metabolic Disease Cancer

Tigapotide (PCK-3145) is a synthetic 15-mer peptide derived from prostate-secretory protein, and acts as an antineoplastic agent. Tigapotide inhibits tumor growth, experimental bone metastasis, and malignancy-associated hypocalcemia. Tigapotide induces apoptosis in prostate cancer cells and tumors, and suppresses the growth of prostate cancer cells. Tigapotide inhibits the production of parathyroid hormone-related protein (PTHrP) in tumors and plasma. Tigapotide reduces plasma calcium levels in hypercalcemic tumor-bearing rats. Tigapotide is applicable for the research of prostate cancer and malignancy-associated hypercalcemia .
loading...
    loading...
Cat. No.: HY-125064
CAS No.: 268741-43-1
Target:  

Src

Research Areas:  

Cancer

AP22408 is a nonpeptide inhibitor against Src SH2 with an IC50 value of 0.3 μM. AP22408 inhibits rabbit osteoclast-mediated resorption of dentine, exhibits bone-targeting properties based on a hydroxyapatite adsorption assay and demonstrates in vivo antiresorptive activity in a parathyroid hormone-induced rat model. AP22408 is proming for rasearch of osteoporosis and other bone-related diseases such as Paget’s disease, osteolytic bone metastasis and hypercalcemia associated with malignancy .
loading...
    loading...
Cat. No.: HY-16497
CAS No.: 848084-84-4
Synonyms: PCK 3145 TFA
Target:  

Apoptosis PTHR

Research Areas:  

Metabolic Disease Cancer

Tigapotide TFA (PCK-3145 TFA) is a synthetic 15-mer peptide derived from prostate-secretory protein, and acts as an antineoplastic agent. Tigapotide TFA inhibits tumor growth, experimental bone metastasis, and malignancy-associated hypocalcemia. Tigapotide TFA induces Apoptosis in prostate cancer cells and tumors, and suppresses the growth of prostate cancer cells. Tigapotide TFA inhibits the production of parathyroid hormone-related protein (PTHrP) in tumors and plasma. Tigapotide TFA reduces plasma calcium levels in hypercalcemic tumor-bearing rats. Tigapotide TFA is applicable for the research of prostate cancer and malignancy-associated hypercalcemia .
loading...
    loading...